当前位置: X-MOL首页全球导师 国内导师 › 沈晓沛

个人简介

教育经历 2007.09-2013.06电子科技大学生命科学与技术学院生物医学工程(肿瘤基因组方向),博士 2002.09-2006.06中南大学信息科学与技术学院计算机科学与技术,本科 工作经历 2019.01-至今南京中医药大学医学与生命学院公共卫生学系教授 2013.12-2018.12约翰霍普金斯大学医学院博士后研究员 社会和学术团体服务 1.美国甲状腺协会会员 2.中国抗癌协会肿瘤标志专业委员会肿瘤测序及大数据分析协作组委员 3.JamaOncology,Bioinformatics,BriefingsinBioinformatics,InternationalJournalofCancer,Thyroid,InternationalJournalofBiologicalSciences等10多个杂志的审稿人 人才项目 江苏省特聘教授(2018)

研究领域

研究方向 1.Ras信号通路上游调节子RasGAP基因家族研究。 2.甲状腺癌相关的分子机制研究以及在临床上的应用。

近期论文

查看导师最新文章 (温馨提示:请注意重名现象,建议点开原文通过作者单位确认)

近年论文列表 1.ShenX#,ZhuG#,LiuR#,ViolaD,EliseiR,PuxedduE,FugazzolaL,ColomboC,JarzabB,CzarnieckaA,LamAK,MianC,VianelloF,YipL,Riesco-EizaguirreG,SantistebanP,O'NeillCJ,SywakMS,Clifton-BlighR,BendlovaB,SýkorováV,XingM.PatientAge-AssociatedMortalityRiskIsDifferentiatedbyBRAFV600EStatusinPapillaryThyroidCancer.JClinOncol.2018,36(5):438-445. 2.WangF#,ZhaoS#,ShenX,ZhuG,LiuR,ViolaD,EliseiR,PuxedduE,FugazzolaL,ColomboC,JarzabB,CzarnieckaA,LamAK,MianC,VianelloF,YipL,Riesco-EizaguirreG,SantistebanP,O'NeillCJ,SywakMS,Clifton-BlighR,BendlovaB,SýkorováV,WangY,XingM.BRAFV600EConfersMaleSexDisease-SpecificMortalityRiskinPatientsWithPapillaryThyroidCancer.JClinOncol.2018,36(27):2787-2795. 3.HuangY#,QuS#,ZhuG,WangF,LiuR,ShenX,ViolaD,EliseiR,PuxedduE,FugazzolaL,ColomboC,JarzabB,CzarnieckaA,LamAK,MianC,VianelloF,YipL,Riesco-EizaguirreG,SantistebanP,O'NeillCJ,SywakMS,Clifton-BlighR,BendlovaB,SýkorovaV,XingM.BRAFV600EMutation-AssistedRiskStratificationofSolitaryIntrathyroidalPapillaryThyroidCancerforPrecisionTreatment.JNatlCancerInst.2018,110(4):362-370. 4.ShenX#,LiuR,XingM.Asix-genotypegeneticprognosticmodelforpapillarythyroidcancer.EndocrRelatCancer.2017,24(1):41-52. 5.ZhangT#,ShenX#,LiuR,ZhuG,BishopJ,XingM.EpigeneticallyupregulatedWIPF1playsamajorroleinBRAFV600E-promotedpapillarythyroidcanceraggressiveness.Oncotarget.2017,8(1):900-914. 6.WangF#,YuX#,ShenX#,ZhuG,HuangY,LiuR,ViolaD,EliseiR,PuxedduE,FugazzolaL,ColomboC,JarzabB,CzarnieckaA,LamAK,MianC,VianelloF,YipL,Riesco-EizaguirreG,SantistebanP,O'NeillCJ,SywakMS,Clifton-BlighR,BendlovaB,SýkorováV,WangY,LiuS,ZhaoJ,ZhaoS,XingM.ThePrognosticValueofTumorMultifocalityinClinicalOutcomesofPapillaryThyroidCancer.JClinEndocrinolMetab.2017,102(9):3241-3250. 7.LiuD,ShenX,ZhuG,XingM.REC8isanoveltumorsuppressorgeneepigeneticallyrobustlytargetedbythePI3Kpathwayinthyroidcancer.Oncotarget.2015,6(36):39211-24 8.ZhangL,HaoC,ShenX,HongG,LiH,ZouX,LiuC,GuoZ.Rank-basedpredictorsforresponseandprognosisofneoadjuvanttaxane-anthracycline-basedchemotherapyinbreastcancer.BreastCancerResTreat.2013,139(2):361-369 9.ShenX,LiS,ZhangL,LiH,HongG,ZhouX,ZhengT,ZhangW,HaoC,ShiT,LiuC,GuoZ.Anintegratedapproachtouncoverdrivergenesinbreastcancermethylationgenomes.PLoSOne.2013,8(4):e61214. 10.ZhuJ,XiaoH,ShenX,WangJ,ZouJ,etal.,GuoZ.Viewingcancergenesfromco-evolvinggenemodules.Bioinformatics.2010,26(7):919-24 国际会议论文摘要 1.ShenX,ZhuG,LiuR,XingM,TheinternationalPTCstudygroup.PatientAge-AssociatedMortalityRiskIsDifferentiatedbyBRAFV600EStatusinPapillaryThyroidCancer,87thAnnualMeetingoftheAmericanThyroidAssociationVictoria,BritishColumbia,2017.10.18-2017.10.22大会报告 2.ShenX,XingM.CoexistingTERTpromoterandBRAFV600EorRASmutationsdefinethemostaggressivepapillarythyroidcancer-aconfirmationintheTCGAdata,86thannualmeetingoftheAmericanThyroidAssociation.Denver,2016.9.21-2016.9.25大会报告 3.ShenX,LiS,GuoZ.Identifyingdrivergenesofbreastcancerbyintegratedanalysisofmethylationandexpressiondatainpaireddisease-normalsamplesofpatients,5thInternationalConferenceon,BioinformaticsandBiomedicalTechnology.Macau,2013.3.17-2013.3.18大会报告

推荐链接
down
wechat
bug